Potential utility of radioprotective agents in the practice of nuclear medicine
Radiopharmaceutical agents are utilized for imaging and treatment in nuclear medicine. Ionizing radiation produces free radicals in the cell that can induce damage to the DNA and lead to side-effects and/or secondary tumors. Radioprotective agents are useful in eliminating or reducing the severity o...
Gespeichert in:
| Veröffentlicht in: | Cancer biotherapy & radiopharmaceuticals 2009-12, Vol.24 (6), p.723-731 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 731 |
|---|---|
| container_issue | 6 |
| container_start_page | 723 |
| container_title | Cancer biotherapy & radiopharmaceuticals |
| container_volume | 24 |
| creator | Hosseinimehr, Seyed Jalal |
| description | Radiopharmaceutical agents are utilized for imaging and treatment in nuclear medicine. Ionizing radiation produces free radicals in the cell that can induce damage to the DNA and lead to side-effects and/or secondary tumors. Radioprotective agents are useful in eliminating or reducing the severity of deleterious cellular effects, which are caused by exposure to internal and/or external irradiation in patients or staff personnel. There are two strategies for the potential use of radioprotective agents in patients, including agents used in patients for selective protective effects, such as reducing mocusitis, myelotoxicity, and kidney damage induced by ionizing radiation in radioiodine and radiolabeled peptide therapy. Second, radioprotective agents can reduce chromosomal aberration induced by gamma- or beta-rays and reduce the risk of tumors in personnel and patients. |
| doi_str_mv | 10.1089/cbr.2009.0635 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_21235452</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A215787916</galeid><sourcerecordid>A215787916</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-20fe5854de33cd438df0439969820bce4ad59335598cc1663d5a312837bb25a3</originalsourceid><addsrcrecordid>eNpdkctLxDAQxoMovo9epXjw1jWPTpscRXzBgh68hzSdaqTbrkkq-N87y6oHySHDzO8LX-Zj7EzwheDaXPk2LiTnZsFrBTvsUAA0pdYgd6nmuipNo-GAHaX0zjmved3sswMSSABQh-zpeco45uCGYs5hCPmrmPoiui5M60gjn8MnFu6VmFSEschvWKyjo7bHDTnOfkAXixV2wYcRT9he74aEpz_3MXu5u325eSiXT_ePN9fL0ittcil5j6Ch6lAp31VKdz2vlDG10ZK3HivXgVEKwGjvRV2rDpwSUqumbSWVx-xy-yyZ_JgxZbsKyeMwuBGnOVkppIIKJIEX_8D3aY4jWbOSV4QZWRG02EKvbkAbxn7K9EU6Ha6Cn0bsA_WvpYBGN0bUJCi3Ah-nlCL2dh3DysUvK7jdxGIpFruJxW5iIf78x8Xc0qb-6N8c1DfBn4c2</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>204212924</pqid></control><display><type>article</type><title>Potential utility of radioprotective agents in the practice of nuclear medicine</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Hosseinimehr, Seyed Jalal</creator><creatorcontrib>Hosseinimehr, Seyed Jalal</creatorcontrib><description>Radiopharmaceutical agents are utilized for imaging and treatment in nuclear medicine. Ionizing radiation produces free radicals in the cell that can induce damage to the DNA and lead to side-effects and/or secondary tumors. Radioprotective agents are useful in eliminating or reducing the severity of deleterious cellular effects, which are caused by exposure to internal and/or external irradiation in patients or staff personnel. There are two strategies for the potential use of radioprotective agents in patients, including agents used in patients for selective protective effects, such as reducing mocusitis, myelotoxicity, and kidney damage induced by ionizing radiation in radioiodine and radiolabeled peptide therapy. Second, radioprotective agents can reduce chromosomal aberration induced by gamma- or beta-rays and reduce the risk of tumors in personnel and patients.</description><identifier>ISSN: 1084-9785</identifier><identifier>EISSN: 1557-8852</identifier><identifier>DOI: 10.1089/cbr.2009.0635</identifier><identifier>PMID: 20025553</identifier><language>eng</language><publisher>United States: Mary Ann Liebert, Inc</publisher><subject>Cell Death - radiation effects ; DNA Damage ; Dosage and administration ; Environmental Exposure - adverse effects ; Gamma Rays - adverse effects ; Gamma Rays - therapeutic use ; Health aspects ; Humans ; Neoplasms, Second Primary - chemically induced ; Nuclear medicine ; Nuclear Medicine - methods ; Positron-Emission Tomography - adverse effects ; Radiation Protection - methods ; Radiation-protective agents ; Radiation-Protective Agents - therapeutic use ; Radiopharmaceuticals - adverse effects ; Radiopharmaceuticals - therapeutic use ; Safety and security measures ; Technetium - adverse effects ; Technetium - therapeutic use ; X-Rays - adverse effects</subject><ispartof>Cancer biotherapy & radiopharmaceuticals, 2009-12, Vol.24 (6), p.723-731</ispartof><rights>COPYRIGHT 2009 Mary Ann Liebert, Inc.</rights><rights>(©) Copyright 2009, Mary Ann Liebert, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-20fe5854de33cd438df0439969820bce4ad59335598cc1663d5a312837bb25a3</citedby><cites>FETCH-LOGICAL-c389t-20fe5854de33cd438df0439969820bce4ad59335598cc1663d5a312837bb25a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20025553$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hosseinimehr, Seyed Jalal</creatorcontrib><title>Potential utility of radioprotective agents in the practice of nuclear medicine</title><title>Cancer biotherapy & radiopharmaceuticals</title><addtitle>Cancer Biother Radiopharm</addtitle><description>Radiopharmaceutical agents are utilized for imaging and treatment in nuclear medicine. Ionizing radiation produces free radicals in the cell that can induce damage to the DNA and lead to side-effects and/or secondary tumors. Radioprotective agents are useful in eliminating or reducing the severity of deleterious cellular effects, which are caused by exposure to internal and/or external irradiation in patients or staff personnel. There are two strategies for the potential use of radioprotective agents in patients, including agents used in patients for selective protective effects, such as reducing mocusitis, myelotoxicity, and kidney damage induced by ionizing radiation in radioiodine and radiolabeled peptide therapy. Second, radioprotective agents can reduce chromosomal aberration induced by gamma- or beta-rays and reduce the risk of tumors in personnel and patients.</description><subject>Cell Death - radiation effects</subject><subject>DNA Damage</subject><subject>Dosage and administration</subject><subject>Environmental Exposure - adverse effects</subject><subject>Gamma Rays - adverse effects</subject><subject>Gamma Rays - therapeutic use</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Neoplasms, Second Primary - chemically induced</subject><subject>Nuclear medicine</subject><subject>Nuclear Medicine - methods</subject><subject>Positron-Emission Tomography - adverse effects</subject><subject>Radiation Protection - methods</subject><subject>Radiation-protective agents</subject><subject>Radiation-Protective Agents - therapeutic use</subject><subject>Radiopharmaceuticals - adverse effects</subject><subject>Radiopharmaceuticals - therapeutic use</subject><subject>Safety and security measures</subject><subject>Technetium - adverse effects</subject><subject>Technetium - therapeutic use</subject><subject>X-Rays - adverse effects</subject><issn>1084-9785</issn><issn>1557-8852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpdkctLxDAQxoMovo9epXjw1jWPTpscRXzBgh68hzSdaqTbrkkq-N87y6oHySHDzO8LX-Zj7EzwheDaXPk2LiTnZsFrBTvsUAA0pdYgd6nmuipNo-GAHaX0zjmved3sswMSSABQh-zpeco45uCGYs5hCPmrmPoiui5M60gjn8MnFu6VmFSEschvWKyjo7bHDTnOfkAXixV2wYcRT9he74aEpz_3MXu5u325eSiXT_ePN9fL0ittcil5j6Ch6lAp31VKdz2vlDG10ZK3HivXgVEKwGjvRV2rDpwSUqumbSWVx-xy-yyZ_JgxZbsKyeMwuBGnOVkppIIKJIEX_8D3aY4jWbOSV4QZWRG02EKvbkAbxn7K9EU6Ha6Cn0bsA_WvpYBGN0bUJCi3Ah-nlCL2dh3DysUvK7jdxGIpFruJxW5iIf78x8Xc0qb-6N8c1DfBn4c2</recordid><startdate>200912</startdate><enddate>200912</enddate><creator>Hosseinimehr, Seyed Jalal</creator><general>Mary Ann Liebert, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7T5</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>200912</creationdate><title>Potential utility of radioprotective agents in the practice of nuclear medicine</title><author>Hosseinimehr, Seyed Jalal</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-20fe5854de33cd438df0439969820bce4ad59335598cc1663d5a312837bb25a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Cell Death - radiation effects</topic><topic>DNA Damage</topic><topic>Dosage and administration</topic><topic>Environmental Exposure - adverse effects</topic><topic>Gamma Rays - adverse effects</topic><topic>Gamma Rays - therapeutic use</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Neoplasms, Second Primary - chemically induced</topic><topic>Nuclear medicine</topic><topic>Nuclear Medicine - methods</topic><topic>Positron-Emission Tomography - adverse effects</topic><topic>Radiation Protection - methods</topic><topic>Radiation-protective agents</topic><topic>Radiation-Protective Agents - therapeutic use</topic><topic>Radiopharmaceuticals - adverse effects</topic><topic>Radiopharmaceuticals - therapeutic use</topic><topic>Safety and security measures</topic><topic>Technetium - adverse effects</topic><topic>Technetium - therapeutic use</topic><topic>X-Rays - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hosseinimehr, Seyed Jalal</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Cancer biotherapy & radiopharmaceuticals</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hosseinimehr, Seyed Jalal</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Potential utility of radioprotective agents in the practice of nuclear medicine</atitle><jtitle>Cancer biotherapy & radiopharmaceuticals</jtitle><addtitle>Cancer Biother Radiopharm</addtitle><date>2009-12</date><risdate>2009</risdate><volume>24</volume><issue>6</issue><spage>723</spage><epage>731</epage><pages>723-731</pages><issn>1084-9785</issn><eissn>1557-8852</eissn><abstract>Radiopharmaceutical agents are utilized for imaging and treatment in nuclear medicine. Ionizing radiation produces free radicals in the cell that can induce damage to the DNA and lead to side-effects and/or secondary tumors. Radioprotective agents are useful in eliminating or reducing the severity of deleterious cellular effects, which are caused by exposure to internal and/or external irradiation in patients or staff personnel. There are two strategies for the potential use of radioprotective agents in patients, including agents used in patients for selective protective effects, such as reducing mocusitis, myelotoxicity, and kidney damage induced by ionizing radiation in radioiodine and radiolabeled peptide therapy. Second, radioprotective agents can reduce chromosomal aberration induced by gamma- or beta-rays and reduce the risk of tumors in personnel and patients.</abstract><cop>United States</cop><pub>Mary Ann Liebert, Inc</pub><pmid>20025553</pmid><doi>10.1089/cbr.2009.0635</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1084-9785 |
| ispartof | Cancer biotherapy & radiopharmaceuticals, 2009-12, Vol.24 (6), p.723-731 |
| issn | 1084-9785 1557-8852 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_21235452 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Cell Death - radiation effects DNA Damage Dosage and administration Environmental Exposure - adverse effects Gamma Rays - adverse effects Gamma Rays - therapeutic use Health aspects Humans Neoplasms, Second Primary - chemically induced Nuclear medicine Nuclear Medicine - methods Positron-Emission Tomography - adverse effects Radiation Protection - methods Radiation-protective agents Radiation-Protective Agents - therapeutic use Radiopharmaceuticals - adverse effects Radiopharmaceuticals - therapeutic use Safety and security measures Technetium - adverse effects Technetium - therapeutic use X-Rays - adverse effects |
| title | Potential utility of radioprotective agents in the practice of nuclear medicine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T10%3A59%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Potential%20utility%20of%20radioprotective%20agents%20in%20the%20practice%20of%20nuclear%20medicine&rft.jtitle=Cancer%20biotherapy%20&%20radiopharmaceuticals&rft.au=Hosseinimehr,%20Seyed%20Jalal&rft.date=2009-12&rft.volume=24&rft.issue=6&rft.spage=723&rft.epage=731&rft.pages=723-731&rft.issn=1084-9785&rft.eissn=1557-8852&rft_id=info:doi/10.1089/cbr.2009.0635&rft_dat=%3Cgale_proqu%3EA215787916%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=204212924&rft_id=info:pmid/20025553&rft_galeid=A215787916&rfr_iscdi=true |